ASH 2021 Lymphoma/DLBCL News
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
These findings were presented at the 2021 American Society of Hematology Annual Meeting.
Polatuzumab Vetodin Plus R-CHP Reduces Risk of Disease Progression or Death in Newly Diagnosed DLBCL
Hervé Tilly, MD, of Centre Henri Becquerel and University of Rouen in France, presented the new research at ASH 2021.
This lack of benefit was seen in the entire study population.
eripheral blood cytopenias may be associated with a higher risk of cancer-related mortality, particularly in Black patients.
This is according to preliminary data from a nonrandomized arm of the SEQUOIA trial.
The CAR T-cell therapy significantly improved event-free survival (EFS) compared with standard of care in patients with LBCL.
According to new research, circulating tumor DNA (ctDNA) accurately reflects tumor burden.
Investigator L. Elizabeth Budde, MD, PhD, presented the research at the 2021 ASH Annual Meeting.
“The results of ZUMA-7 herald a paradigm shift in how we treat large B-cell lymphoma."
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.